Bailey Fields and Todd Kennedy, two individuals who have struggled with weight management, have found success with compounded semaglutide medications, which they claim have been effective and affordable alternatives for weight loss. Fields, a 27-year-old resident of Hutchison, MN, diagnosed with polycystic ovarian syndrome (PCOS), and Kennedy, a 45-year-old from Lenoir City, TN, who has battled weight issues for two decades, have both experienced significant weight loss—35 pounds and 30 pounds, respectively—after using these compounded drugs.
However, their access to these medications may soon be restricted due to an upcoming ban by the Food and Drug Administration (FDA) on compounded semaglutide. This ban, set to take effect on April 22, follows a similar prohibition on compounded tirzepatide that began on March 19. The FDA's decision stems from a recent federal court ruling against the outsourcing facilities that produce these compounded medications, which the FDA does not formally approve, raising concerns about their safety and efficacy.
In light of the ban, major pharmaceutical companies Eli Lilly and Novo Nordisk are taking steps to make their brand-name weight loss drugs, Zepbound and Wegovy, more affordable. Eli Lilly plans to sell its Zepbound medication for $499 a month for eligible customers, while Novo Nordisk has announced similar pricing for Wegovy. Despite these efforts, Fields and Kennedy remain uncertain if they can afford these brand-name alternatives, especially since their health insurance does not cover these drugs.
Both individuals express concern about potential weight regain without access to their current medication and advocate for continued availability of diverse weight loss options. They emphasize the importance of these medications in managing their weight effectively.